Compugen Ltd (CGEN)

4.25
0.10 2.30
NASDAQ : Health Care
Prev Close 4.35
Open 4.30
Day Low/High 4.20 / 4.35
52 Wk Low/High 4.32 / 7.79
Volume 32.37K
Avg Volume 133.50K
Exchange NASDAQ
Shares Outstanding 51.13M
Market Cap 224.98M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Compugen Announces Addition Of Prof. Miriam Merad To Its Scientific Advisory Board

Compugen Announces Addition Of Prof. Miriam Merad To Its Scientific Advisory Board

Prof. Merad is a distinguished leader in myeloid biology for the development of novel cancer immunotherapies

Compugen Enters Oversold Territory

Compugen Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen is Now Oversold (CGEN)

Compugen is Now Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen's CGEN-15001 Demonstrates Restoration Of Immune Tolerance In Autoimmunity

Compugen's CGEN-15001 Demonstrates Restoration Of Immune Tolerance In Autoimmunity

New data shows restoration of antigen-specific immune tolerance and re-establishment of immune homeostasis

Oversold Conditions For Compugen (CGEN)

Oversold Conditions For Compugen (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Discloses Its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint

Compugen Discloses Its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint

Enhanced Therapeutic Effect Anticipated for Antibody Treatment Combining the Targeting of Both TIGIT and CGEN-15029

Compugen Immune Checkpoint Program Demonstrates Potential For Development Of New Cancer Immunotherapy Treatments

Compugen Immune Checkpoint Program Demonstrates Potential For Development Of New Cancer Immunotherapy Treatments

New preclinical results for CGEN-15029 presented in late-breaking session at Annual Meeting of the Society for Immunotherapy of Cancer

Compugen To Host R&D Day On December 7, 2016 In New York

Compugen To Host R&D Day On December 7, 2016 In New York

Event to focus on the Company's immuno-oncology programs; Live webcast will be available via the Company's website

Compugen Third Quarter Financial Statements To Be Released November 7, 2016

Compugen Third Quarter Financial Statements To Be Released November 7, 2016

Third quarter conference call postponed to November 16 to allow discussion of new CGEN-15029 data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer

Compugen To Present At The Annual Meeting Of The Society For Immunotherapy Of Cancer Next Month

Compugen To Present At The Annual Meeting Of The Society For Immunotherapy Of Cancer Next Month

Presentation will include new data on CGEN-15029, a Compugen-discovered novel immune checkpoint target, including functional characterization and antibody blockade

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Discloses Development Of Enhanced LINKS Platform Utilized For The Discovery Of Myeloid Targets For Cancer Immunotherapy

Compugen Discloses Development Of Enhanced LINKS Platform Utilized For The Discovery Of Myeloid Targets For Cancer Immunotherapy

Myeloid target candidates predicted in silico using enhanced LINKS platform are now being experimentally validated

Compugen Discloses Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program

Compugen Discloses Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program

IND filing for COM701 anticipated next year

Compugen Enters Oversold Territory (CGEN)

Compugen Enters Oversold Territory (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.